Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Subscribe To Our Newsletter & Stay Updated